11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 599,255 | $13,105,707 | +76% | 0.12% |
| 2. | Bayforest Capital Theodoros Tsagaris | 52,338 | $609,036 | +432% | 0.5% |
| 3. | 23,400 | $511,758 | -59% | 0% | |
| 4. | 700 | $15,309 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.82 | 183 | Officer | 47,955 | 2025-03-17 | Filing | |
| $25.10 | 5,569 | 138,730 | 2025-03-05 | Filing | ||
| $28.54 | 363 | Officer | 83,945 | 2025-02-11 | Filing | |
| $29.52 | 695 | Officer | 144,299 | 2025-01-29 | Filing | |
| $29.52 | 695 | Officer | 84,050 | 2025-01-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,130,356 | $221,550,886 | 0% | |
| 2. | 6,329,598 | $138,428,308 | 0% | |
| 3. | 2,477,531 | $54,183,603 | 0.04% | |
| 4. | 1,776,576 | $38,853,717 | 0.02% | |
| 5. | 964,499 | $21,093,593 | 0% |
News See All
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript May 7, 2025Apellis Pharmaceuticals, Inc. misses on earnings expectations.
11 Oversold NASDAQ Stocks to Buy Right Now
On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC's 'Squawk on the Street' to discuss market outlooks and what investors should look at in the current market...
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript February 28, 2025Apellis Pharmaceuticals, Inc. beats earnings expectations.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...